In Vitro Activity of JPC 2067 Alone and in Combination with Sulfamethoxazole against Nocardia Species | Zendy

Swagatam Mookherjee | Zendy; Carolyn Shoen | Zendy; Michael H. Cynamon | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro Activity of JPC 2067 Alone and in Combination with Sulfamethoxazole against Nocardia Species

Author(s) -

Swagatam Mookherjee,

Carolyn Shoen,

Michael H. Cynamon

Publication year - 2011

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.05855-11

Subject(s) - nocardia , sulfamethoxazole , in vitro , microbiology and biotechnology , biology , chemistry , antibiotics , bacteria , biochemistry , genetics

JPC 2067 is a novel dihydrotriazine dihydrofolate reductase inhibitor that is being developed as an antimalarial therapeutic. We evaluated the in vitro activity of JPC 2067 alone and in combination with sulfamethoxazole (SMX) against a panel of nocardia isolates. The MIC(50)s and MIC(90)s for JPC 2067, SMX, and the combination were 0.125 μg/ml and 4 μg/ml, 16 μg/ml and 32 μg/ml, and 0.03 μg/ml and 2 μg/ml, respectively. JPC 2067 alone and in combination with SMX should be evaluated further to understand its clinical potential.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research